{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:46Z","timestamp":1784347426590,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106826","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:12:12Z","timestamp":1761898332000},"page":"106826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7101-0949","authenticated-orcid":false,"given":"Assunta","family":"Bianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-9044","authenticated-orcid":false,"given":"Arianna","family":"Aruanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-2297","authenticated-orcid":false,"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4356-3201","authenticated-orcid":false,"given":"Alessandra","family":"Cicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-838X","authenticated-orcid":false,"given":"David","family":"Longhino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7499-2941","authenticated-orcid":false,"given":"Marco","family":"Bisurgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-6584","authenticated-orcid":false,"given":"Francesca","family":"Col\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7109-6780","authenticated-orcid":false,"given":"Vincenzo","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-746X","authenticated-orcid":false,"given":"Angela","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-6855","authenticated-orcid":false,"given":"Alessandro","family":"Buonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-114X","authenticated-orcid":false,"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106826_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840238","article-title":"Case report: rapid desensitization to ocrelizumab for multiple sclerosis is effective and safe","volume":"13","author":"Aun","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106826_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40521-020-00242-2","article-title":"Hypersensitivity reactions to biologicals: from bench to bedside","volume":"7","author":"Akarsu","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"issue":"1","key":"10.1016\/j.msard.2025.106826_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.msard.2025.106826_bib0013","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs \u2013 an ENDA \/EAACI drug allergy interest group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy."},{"issue":"3","key":"10.1016\/j.msard.2025.106826_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs."},{"issue":"5","key":"10.1016\/j.msard.2025.106826_bib0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaip.2017.04.044","article-title":"First-dose anaphylaxis to infliximab: a case of mammalian meat allergy","volume":"5","author":"Chitnavis","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"11","key":"10.1016\/j.msard.2025.106826_bib0015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106826_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106826_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106826_bib0017","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4103\/aian.aian_526_22","article-title":"Successful rapid desensitization of a pediatric multiple sclerosis patient with anaphylaxis to ocrelizumab","volume":"25","author":"Karaaslan","year":"2022","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106826_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00415-023-12082-6","article-title":"Serum sickness in a multiple sclerosis patient treated with ocrelizumab","volume":"271","author":"Mantero","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106826_bib0002","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106826_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106826_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1352458520910486","article-title":"A possible case of serum sickness after ocrelizumab infusion","volume":"27","author":"Moreira Ferreira","year":"2021","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.msard.2025.106826_bib0012","unstructured":"National Cancer Institute, U.S. department of health and human services. National cancer institute. Common terminology criteria for adverse events (CTCAE) version 4.03. Bethesda (MD) [Internet]. 2010. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Documentation\/CTCAE_Governance_2010-03-11.pdf."},{"issue":"9","key":"10.1016\/j.msard.2025.106826_bib0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin. Drug. Saf."},{"key":"10.1016\/j.msard.2025.106826_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102058","article-title":"Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy","volume":"42","author":"Nylund","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106826_bib0009","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7224\/1537-2073.2022-080","article-title":"Serum sickness\/serum sickness-like reactions following ocrelizumab infusion in 2 patients with multiple sclerosis","volume":"25","author":"Rjeily","year":"2023","journal-title":"Int. J. MS Care"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:38:24Z","timestamp":1784345904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"alternative-id":["S2211034825005681"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106826","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106826"}}